Biopharmaceutical company utilizing its XmAb® technology to develop antibody therapeutics for cancer and autoimmune diseases.
Xencor, Inc. is a clinical stage biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibody and cytokine therapeutics aimed at treating cancer and autoimmune diseases. The company's diverse portfolio includes innovative treatments such as Sotrovimab, designed to target the SARS-CoV-2 virus, and Ultomiris, indicated for patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Additionally, Xencor offers Monjuvi for relapsed or refractory diffuse large B-cell lymphoma, showcasing its commitment to advancing therapies for critical medical conditions.
Xencor's pipeline is robust, featuring promising candidates like Plamotamab, a tumor-targeted antibody undergoing Phase I trials for non-Hodgkin lymphoma, and Vudalimab, a bispecific antibody in Phase II trials for metastatic castration-resistant prostate cancer and other solid tumors. The company is also advancing Tidutamab in Phase II trials for neuroendocrine tumors, highlighting its dedication to addressing complex medical needs across various disease states.
Founded in 1997 and headquartered in Monrovia, California, Xencor leverages its extensive research and development capabilities to explore novel therapeutic avenues. The company's innovative pipeline includes XmAb306 and XmAb104 for solid tumors, XmAb564 for autoimmune diseases, and AMG 509 for prostate cancer, underscoring its broad therapeutic focus and commitment to advancing patient care.
In addition to its internal developments, Xencor collaborates through strategic partnerships, including a license agreement with Caris Life Sciences, to enhance its capabilities and expand its reach in the biopharmaceutical sector. With ongoing clinical trials for multiple promising candidates, Xencor continues to drive innovation and pursue transformative treatments for a wide range of medical conditions.